{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:13:25Z","timestamp":1757704405894},"reference-count":55,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,6,18]],"date-time":"2002-06-18T00:00:00Z","timestamp":1024358400000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Toxicology"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:p> <jats:italic>Abstract:<\/jats:italic>Tolterodine and its major active 5\u2010hydroxymethyl metabolite (5\u2010HM) are potent muscarinic receptor antagonists that show selectivity for the urinary bladder over salivary glands <jats:italic>in vivo<\/jats:italic>. This tissue selectivity cannot be attributed to muscarinic receptor subtype selectivity, since both compounds are non\u2010selective with respect to the M<jats:sub>1<\/jats:sub>\u2013M<jats:sub>5<\/jats:sub> receptor subtypes. The aim of the present <jats:italic>in vitro<\/jats:italic> study was to determine the specificity of tolterodine and 5\u2010HM for muscarinic receptors compared to other potential cellular targets. Carbachol\u2010induced contractions of isolated guinea pig bladder were effectively inhibited by tolterodine (IC<jats:sub>50<\/jats:sub> 14 nM) and 5\u2010HM (IC<jats:sub>50<\/jats:sub> 5.7 nM). Tolterodine and 5\u2010HM were weak inhibitors of effects mediated by \u03b1\u2010adrenergic receptors (rat portal vein), histamine receptors (guinea pig ileum) and calcium channels (guinea pig potassium\u2010depolarised urinary bladder, spontaneously beating right atria and electrically\u2010driven right papillary muscle). The IC<jats:sub>50<\/jats:sub> values were in the \u03bcM range and the antimuscarinic potency of tolterodine was 27, 200 and 370\u2013485 times higher, respectively, than its potency in blocking histamine receptors, \u03b1\u2010adrenoceptors and calcium channels. The active metabolite, 5\u2010HM, was &gt;900 times less potent at these sites than at bladder muscarinic receptors. Radioligand binding data on 54 different receptors and binding sites showed that tolterodine and 5\u2010HM bind with significant affinity only at muscarinic receptors. In conclusion, the results of the present study indicate that both tolterodine and 5\u2010HM are specific muscarinic receptor antagonists. The tissue selectivity of these agents <jats:italic>in vivo<\/jats:italic> cannot therefore be explained by secondary pharmacological actions.<\/jats:p>","DOI":"10.1034\/j.1600-0773.2002.900506.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T18:55:44Z","timestamp":1047495344000},"page":"260-267","source":"Crossref","is-referenced-by-count":16,"title":["Tolterodine and its Active 5\u2010Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists"],"prefix":"10.1111","volume":"90","author":[{"given":"Lisbeth","family":"Nilvebrant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,6,18]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00717.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198835040-00006"},{"key":"e_1_2_5_4_1","first-page":"253","article-title":"The pharmacology of lower urinary tract smooth muscles and penile erectile tissues","volume":"45","author":"Andersson K.\u2010E.","year":"1993","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_5_5_1","first-page":"447","volume-title":"Incontinence","author":"Andersson K.\u2010E.","year":"1999"},{"key":"e_1_2_5_6_1","first-page":"633","article-title":"Torsades de pointes and terodiline","volume":"338","author":"Andrews N. P.","year":"1991","journal-title":"Lancet"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00599-2"},{"key":"e_1_2_5_8_1","first-page":"117","article-title":"[3H]\u2010(+)\u2010pentazocine: a potent and highly selective benzomorphan\u2010based probe for sigma\u20101 receptors","volume":"3","author":"Bowen W. D.","year":"1993","journal-title":"Mol. Neuropharmacol."},{"key":"e_1_2_5_9_1","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne N.","year":"1997","journal-title":"Int. J. Clin. Pharmacol. Therap."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90341-7"},{"issue":"5","key":"e_1_2_5_11_1","first-page":"253","article-title":"Tolterodine once\u2010daily: selectivity for the bladder over effects on salivation compared to Ditropan XL","volume":"165","author":"Chapple C.","year":"2001","journal-title":"J. Urol."},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90481-4"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01993161"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001920050014"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.17.040177.001053"},{"key":"e_1_2_5_17_1","first-page":"308","article-title":"Pharmacological in vitro and in vivo profile of DD 01 \u2013 a major metabolite of tolterodine","volume":"15","author":"Gillberg P.\u2010G.","year":"1996","journal-title":"Neurourol. Urodyn."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1985.tb08854.x"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(79)90202-4"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03191308"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498259209053145"},{"key":"e_1_2_5_22_1","first-page":"867","article-title":"R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine","volume":"247","author":"Kachur J. F.","year":"1988","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.113.145"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb12054.x"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-4295(98)00629-3"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(84)90340-0"},{"key":"e_1_2_5_27_1","first-page":"29","article-title":"The efficacy, tolerability and safety profile of tolterodine in the treatment of overactive\/unstable bladder","volume":"11","author":"Malone\u2010Lee J. G.","year":"2000","journal-title":"Rev. Contemp. Pharmacother."},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6790.1469-c"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03188807"},{"key":"e_1_2_5_30_1","first-page":"524","article-title":"Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders","volume":"14","author":"Naerger H.","year":"1995","journal-title":"Neurourol. Urodyn."},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90484-0"},{"key":"e_1_2_5_32_1","unstructured":"Nilvebrant L.:Tolterodine and terodiline \u2013 different pharmacological profiles. Proceedings of the 27th Annual Meeting of the International Continence Society Yokohama (Japan) September 23\u2013\u201326 1997."},{"key":"e_1_2_5_33_1","first-page":"13","article-title":"The mechanism of action of tolterodine","volume":"11","author":"Nilvebrant L.","year":"2000","journal-title":"Rev. Contemp. Pharmacother."},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(01)01051-7"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)89661-6"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb02064.x"},{"key":"e_1_2_5_37_1","first-page":"433","article-title":"The in vitro pharmacological profile of tolterodine \u2013 new agent for the treatment of urinary urge incontinence","volume":"13","author":"Nilvebrant L.","year":"1994","journal-title":"Neurourol. Urodyn."},{"key":"e_1_2_5_38_1","unstructured":"Nilvebrant L. G.Glas&B.Sparf:A metabolite of oxybutynin N\u2010desethyl\u2010oxybutynin exhibits selectivity for muscarinic receptors in cerebral cortex (M1) and parotid gland (M3). Proceedings of the 19th Annual Meeting of the International Continence Society Ljubljana (Yugoslavia) September 7\u20139 1989."},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00057-X"},{"key":"e_1_2_5_40_1","first-page":"562","article-title":"Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 receptors and in vivo effects on urinary bladder contraction, mydriasis and salivation in guinea pigs","volume":"256","author":"Noronha\u2010Blob L.","year":"1991","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"e_1_2_5_41_1","first-page":"593","article-title":"SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies","volume":"255","author":"Polster P.","year":"1990","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"e_1_2_5_42_1","first-page":"289","article-title":"Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind H.","year":"1998","journal-title":"Drug Metab. Disp."},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb13002.x"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.5.1658"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199006000-00006"},{"key":"e_1_2_5_47_1","first-page":"67","article-title":"Anticholinergic properties of propiverine and its metabolites","volume":"45","author":"Siegmund W.","year":"1990","journal-title":"Pharmazie"},{"key":"e_1_2_5_48_1","first-page":"1012","article-title":"Comparison of the antimuscarinic and the antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of terodiline","volume":"48","author":"Smith E. R.","year":"1998","journal-title":"Arzneimittelforsch. (Drug Res.)"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930140606"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265918"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00167244"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1991.tb01308.x"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.08-09-03354.1988"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65148-6"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199506030-00007"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00036-9"}],"container-title":["Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0773.2002.900506.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0773.2002.900506.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0773.2002.900506.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T18:58:45Z","timestamp":1697309925000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0773.2002.900506.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1034\/j.1600-0773.2002.900506.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0773.2002.900506.x","archive":["Portico"],"relation":{},"ISSN":["0901-9928"],"issn-type":[{"value":"0901-9928","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}